Cobimetinib联合阿替利珠单抗对比帕博利珠单抗一线治疗BRAFV600野生型晚期黑色素瘤:III期IMspire170研究主要结果
IMspire170是一项国际随机开放标签III期研究,纳入446例既往未治疗的BRAFV600野生型晚期黑色素瘤患者,1:1随机接受cobimetinib联合阿替利珠单抗或帕博利珠单抗单药治疗。主要终点为独立评审委员会评估的无进展生存期(PFS),联合组中位PFS为5.5个月(95%CI 3.8-7.2),帕博利珠单抗组为5.7个月(95%CI 3.7-9.6),分层风险比1.15(95%CI 0.88-1.50),P=0.30。联合治疗未改善PFS,且3-5级不良事件和严重不良事件发生率更高。
要点
- 在BRAFV600野生型晚期黑色素瘤一线治疗中,cobimetinib联合阿替利珠单抗未优于帕博利珠单抗单药。
- 联合组中位PFS 5.5个月 vs 帕博利珠单抗组5.7个月,分层HR 1.15(95%CI 0.88-1.50),P=0.30。
- 联合组3-5级不良事件和严重不良事件发生率更高,不支持该联合方案用于该人群。
核心结论
- 在既往未治疗的BRAFV600野生型晚期黑色素瘤患者中,cobimetinib联合阿替利珠单抗对比帕博利珠单抗单药未改善PFS。
研究设计与样本
- IMspire170为国际、随机、开放标签、III期研究,共随机446例患者。
- 患者1:1随机接受cobimetinib(60 mg,第1-21天)联合阿替利珠单抗(840 mg,每2周)或帕博利珠单抗(200 mg,每3周)单药治疗。
- 主要终点为独立评审委员会评估的意向治疗人群PFS。
主要发现
- 联合组中位PFS为5.5个月(95%CI 3.8-7.2),帕博利珠单抗组为5.7个月(95%CI 3.7-9.6),分层HR 1.15(95%CI 0.88-1.50),P=0.30。
- 预设亚组中PFS的风险比一致。
- 探索性生物标志物分析显示,较高的肿瘤突变负荷与两组临床结局改善相关。
关键数值与推荐
- 联合组 vs 帕博利珠单抗组的3-5级不良事件:血肌酸磷酸激酶升高10.0% vs 0.9%,腹泻7.7% vs 1.9%,皮疹6.8% vs 0.9%,高血压6.4% vs 3.7%,痤疮样皮炎5.0% vs 0。
- 严重不良事件发生率:联合组44.1%,帕博利珠单抗组20.8%。
临床怎么用
- 对于BRAFV600野生型晚期黑色素瘤的一线治疗,不应常规采用cobimetinib联合阿替利珠单抗方案。
- 帕博利珠单抗单药仍是该人群的合理治疗选择之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAFV600 wild-type advanced melanoma. PATIENTS AND METHODS: IMspire170 was an international, randomized, open-label, phase III study. Patients were randomized 1 : 1 to receive cobimetinib (60 mg, days 1-21) plus anti-programmed death-ligand 1 atezolizumab (840 mg every 2 weeks) in 28-day cycles or anti-programmed death-1 pembrolizumab (200 mg every 3 weeks) alone until loss of clinical benefit, unacceptable toxicity, or consent withdrawal. The primary outcome was progression-free survival (PFS), assessed by an independent review committee in the intention-to-treat population. RESULTS: Between 11 December 2017, and 29 January 2019, 446 patients were randomized to receive cobimetinib plus atezolizumab (n = 222) or pembrolizumab (n = 224). Median follow-up was 7.1 months [interquartile range (IQR) 4.8-9.9] for cobimetinib plus atezolizumab and 7.2 months (IQR 4.9-10.1) for pembrolizumab. Median PFS was 5.5 months [95% confidence interval (CI) 3.8-7.2] with cobimetinib plus atezolizumab versus 5.7 months (95% CI 3.7-9.6) with pembrolizumab [stratified hazard ratio 1.15 (95% CI 0.88-1.50); P = 0.30]. Hazard ratios for PFS were consistent across prespecified subgroups. In exploratory biomarker analyses, higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms. The most common grade 3-5 adverse events (AEs) were increased blood creatine phosphokinase (10.0% with cobimetinib plus atezolizumab versus 0.9% with pembrolizumab), diarrhea (7.7% versus 1.9%), rash (6.8% versus 0.9%), hypertension (6.4% versus 3.7%), and dermatitis acneiform (5.0% versus 0). Serious AEs occurred in 44.1% of patients with cobimetinib plus atezolizumab and 20.8% with pembrolizumab. CONCLUSION: Cobimetinib plus atezolizumab did not improve PFS compared with pembrolizumab monotherapy in patients with BRAFV600 wild-type advanced melanoma.
引用
- Gogas H, Dréno B, Larkin J, et al. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol. 2020. PMID: 33309774. doi:10.1016/j.annonc.2020.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。